Literature DB >> 30891123

1H-Pyrrolo[3,2-b]pyridine GluN2B-Selective Negative Allosteric Modulators.

Christa C Chrovian1, Akinola Soyode-Johnson1, Jessica L Wall1, Jason C Rech1, Jeff Schoellerman1, Brian Lord1, Kevin J Coe1, Nicholas I Carruthers1, Leslie Nguyen1, Xiaohui Jiang1, Tatiana Koudriakova1, Bartosz Balana1, Michael A Letavic1.   

Abstract

Herein, we disclose a series of selective GluN2B negative allosteric modulators containing a 1H-pyrrolo[3,2-b]pyridine core. Lead optimization efforts included increasing brain penetration as well as decreasing cytochrome P450 inhibition and hERG channel binding. The series was also optimized to reduce metabolic turnover in human and rat. Compounds 9, 25, 30, and 34 have good in vitro GluN2B potency and good predicted absorption, but moderate to high projected clearance. They were assessed in vivo to determine their target engagement. All four compounds achieved >75% receptor occupancy after an oral dose of 10 mg/kg in rat. Compound 9 receptor occupancy was measured in a dose-response experiment, and its ED50 was found to be 2.0 mg/kg.

Entities:  

Year:  2019        PMID: 30891123      PMCID: PMC6421534          DOI: 10.1021/acsmedchemlett.8b00542

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  13 in total

1.  A Randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder.

Authors:  Lobna Ibrahim; Nancy Diaz Granados; Libby Jolkovsky; Nancy Brutsche; David A Luckenbaugh; W Joseph Herring; William Z Potter; Carlos A Zarate
Journal:  J Clin Psychopharmacol       Date:  2012-08       Impact factor: 3.153

Review 2.  NMDA receptor subunits: function and pharmacology.

Authors:  Pierre Paoletti; Jacques Neyton
Journal:  Curr Opin Pharmacol       Date:  2006-11-07       Impact factor: 5.547

Review 3.  Allosteric modulators of NR2B-containing NMDA receptors: molecular mechanisms and therapeutic potential.

Authors:  Laetitia Mony; James N C Kew; Martin J Gunthorpe; Pierre Paoletti
Journal:  Br J Pharmacol       Date:  2009-07-08       Impact factor: 8.739

4.  Subunit-specific mechanisms and proton sensitivity of NMDA receptor channel block.

Authors:  Shashank M Dravid; Kevin Erreger; Hongjie Yuan; Katherine Nicholson; Phuong Le; Polina Lyuboslavsky; Antoine Almonte; Ernest Murray; Cara Mosely; Jeremy Barber; Adam French; Robert Balster; Thomas F Murray; Stephen F Traynelis
Journal:  J Physiol       Date:  2007-02-15       Impact factor: 5.182

5.  Mapping the binding site of the neuroprotectant ifenprodil on NMDA receptors.

Authors:  Florent Perin-Dureau; Julie Rachline; Jacques Neyton; Pierre Paoletti
Journal:  J Neurosci       Date:  2002-07-15       Impact factor: 6.167

6.  Comparison of the ex vivo receptor occupancy profile of ketamine to several NMDA receptor antagonists in mouse hippocampus.

Authors:  Brian Lord; Cindy Wintmolders; Xavier Langlois; Leslie Nguyen; Tim Lovenberg; Pascal Bonaventure
Journal:  Eur J Pharmacol       Date:  2013-07-16       Impact factor: 4.432

Review 7.  Presynaptic glutamate receptors: physiological functions and mechanisms of action.

Authors:  Paulo S Pinheiro; Christophe Mulle
Journal:  Nat Rev Neurosci       Date:  2008-05-09       Impact factor: 34.870

8.  An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder.

Authors:  Sheldon H Preskorn; Bryan Baker; Sheela Kolluri; Frank S Menniti; Michael Krams; Jaren W Landen
Journal:  J Clin Psychopharmacol       Date:  2008-12       Impact factor: 3.153

9.  Effects of a NR2B selective NMDA glutamate antagonist, CP-101,606, on dyskinesia and Parkinsonism.

Authors:  John G Nutt; Steven A Gunzler; Trish Kirchhoff; Penelope Hogarth; Jerry L Weaver; Michael Krams; Brenda Jamerson; Frank S Menniti; Jaren W Landen
Journal:  Mov Disord       Date:  2008-10-15       Impact factor: 10.338

10.  NMDA Receptor Antagonists for Treatment of Depression.

Authors:  Zeynep Ates-Alagoz; Adeboye Adejare
Journal:  Pharmaceuticals (Basel)       Date:  2013-04-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.